For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 59,990 | |||
| General and administrative | 24,124 | |||
| Total operating expenses | 84,114 | |||
| Loss from operations | -84,114 | |||
| Interest income | 6,479 | |||
| Other expense, net | -270 | |||
| Total other income, net | 6,209 | |||
| Net loss | -77,905 | |||
| Basic EPS | -2.02 | |||
| Diluted EPS | -2.02 | |||
| Basic Average Shares | 38,509,281 | |||
| Diluted Average Shares | 38,509,281 | |||
Acrivon Therapeutics, Inc. (ACRV)
Acrivon Therapeutics, Inc. (ACRV)